3. Intangible Assets, Goodwill and Other

3 Months Ended

Mar. 31, 2021

GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):


	Life Science		Clinical Diagnostics		Total











Balances as of March 31, 2021 and December 31, 2020:
Goodwill	277.9		349.2		627.1
Accumulated impairment losses	(41.8)		(293.4)		(335.2)
Goodwill, net	$	236.1	$	55.8	$	291.9

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):


	March 31, 2021
	Weighted-Average Remaining Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.47	$	112.4	$	(85.6)	$	26.8
Know how	4.50	192.7		(172.6)		20.1
Developed product technology	13.83	217.1		(108.6)		108.5
Licenses	7.51	65.2		(38.0)		27.2
Tradenames	7.71	6.4		(4.2)		2.2
Covenants not to compete	3.66	4.6		(2.2)		2.4

Other	—	0.1		(0.1)		—
Total definite-lived intangible assets		598.5		(411.3)		187.2
In-process research and development		4.6		—		4.6
Total purchased intangible assets		$	603.1	$	(411.3)	$	191.8


	December 31, 2020
	Weighted-Average Remaining Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.51	$	116.6	$	(87.2)	$	29.4
Know how	4.75	196.6		(175.4)		21.2
Developed product technology	14.00	218.1		(107.1)		111.0
Licenses	7.73	65.6		(37.4)		28.2
Tradenames	7.82	6.6		(4.2)		2.4
Covenants not to compete	3.87	4.5		(2.0)		2.5

Other	—	0.1		(0.1)		—
Total definite-lived intangible assets		608.1		(413.4)		194.7
In-process research and development		4.8		—		4.8
Total purchased intangible assets		$	612.9	$	(413.4)	$	199.5

Amortization expense related to purchased intangible assets is as follows (in millions):